Children and HIV/AIDS: from research to policy and action in resource-limited settings

Joanna Orne-Gliemann[a], Renaud Becquet[a,b,c], Didier K. Ekouevi[a], Valériane Leroy[a,b], Freddy Perez[a] and François Dabis[a,b]

Introduction

In 2006 HIV/AIDS was the leading cause of death worldwide for individuals aged 15–49 years. The pandemic is having a dramatic impact on child mortality, with 380 000 children having died of AIDS-related diseases [1]. The same year, it was estimated that 2.3 million children under the age of 15 years were living with the virus, mainly as a result of mother-to-child transmission of HIV (MTCT) [1]. More than 90% of these children were living in sub-Saharan Africa. The number of children orphaned after their parent(s) have died from AIDS is also rising dramatically, reaching 15.2 million children worldwide in 2005. More than five million children are currently living with HIV-related chronically ill family members and will become orphans unless appropriate care and treatment is provided [2].

Considerable progress has been achieved in industrialized countries towards the prevention of new paediatric HIV infections, the provision of adequate treatment to HIV-infected children, and support to vulnerable children and orphans affected by HIV/AIDS. But for many children, especially in low–incomes countries, adequate prevention, care and treatment still remains inaccessible.

The aim of this article is to review the state of knowledge in the field of paediatric HIV/AIDS, to describe the research undertaken over the past decade, and to assess the level of implementation of research results, focusing mainly on the experience of African countries.

The prevention of mother-to-child transmission of HIV

Most paediatric HIV infections are the result of MTCT, which can occur in the peripartum, during late pregnancy and delivery, and postpartum through breast-feeding. In the absence of any intervention, the risk of MTCT is 15–30% in non-breastfeeding populations and 20–45% among populations who practise prolonged breastfeeding, which is of particular concern in Africa [3]. In developed countries, the risk of MTCT can be reduced to 2% through the combination of several preventive interventions: antiretroviral prophylaxis administered to women during pregnancy and labour and to infants during the first weeks of life, elective caesarean delivery, and the complete avoidance of breastfeeding [4]. In low–income countries, however, caesarean delivery is seldom feasible [5] and it is often neither acceptable nor safe for mothers to refrain from breastfeeding in the

From the [a]Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, the [b]INSERM, Unité 897, Centre de recherche 'Epidémiologie et Biostatistique', Bordeaux, France, and the [c]Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa.
Correspondence to Joanna Orne-Gliemann, ISPED (Case 11), Université Victor Segalen – Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux, France.
Tel: +33 5 57 57 45 17; fax: +33 5 57 57 45 28; e-mail: joanna.orne-gliemann@isped.u-bordeaux2.fr

absence of any specific nutritional support. In these settings, efforts to prevent HIV transmission in infants were thus initially focused on peripartum MTCT.

Since 1998, the efficacy of short-course peripartum antiretroviral regimens administered to HIV-infected pregnant mothers and their infants has been established within African and Thai randomized clinical trials [6–9]. These regimens, involving three antiretroviral drugs, zidovudine, lamivudine and nevirapine, resulted in MTCT risk reductions ranging from 37 to 77% compared with no intervention. Combination regimens are more efficacious than single-drug regimens [10–12], as are regimens of longer durations compared with short-course and single-dose regimens [13]. The World Health Organization (WHO) currently recommends the following antiretroviral regimen for preventing MTCT among women who do not have indications for antiretroviral therapy (ART) for their own health: zidovudine from 28 weeks of pregnancy; zidovudine and lamivudine plus single-dose nevirapine at the onset of labour; maternal zidovudine plus lamivudine for 7 days after delivery; and single-dose nevirapine plus one week of zidovudine for newborn infants [4]. Within low-income countries who are able to deliver only a minimal range of antiretroviral drugs, the single-dose nevirapine regimen remains the most feasible and least expensive strategy, with a residual peripartum transmission rate of 12% [7,14]. Although the selection of nevirapine-resistant virus after the administration of single-dose nevirapine is frequent [15,16], this biological event can be reduced by the addition to single-dose nevirapine of a short 3-day postpartum combination of maternal zidovudine plus lamivudine [17,18]. It is now clearly acknowledged that pregnant women in need of ART should initiate treatment as soon as possible [4]. ART improves the woman's health and is also expected to reduce the maternal HIV plasma viral load, the strongest determinant of MTCT [19,20]. Although ART initiated before or during pregnancy may be associated with adverse pregnancy outcomes, in particular with prematurity [21,22], to date the benefits of antiretroviral exposure greatly outweigh any observed risk for the mother or infant [23].

Research has also addressed the long-term efficacy of peripartum interventions, e.g. after the complete cessation of breastfeeding. A diminution or even a loss of efficacy of short-course antiretroviral regimens administered in the peripartum in African breastfeeding populations was reported [24]. Postnatal interventions aimed at the prevention of HIV through breastfeeding are thus critical to achieve an overall substantial and sustainable reduction in MTCT. Breastfeeding is the most nutritionally adequate infant feeding practice, also providing protection against diarrhoea and acute respiratory infections, especially in early life [25]. In the absence of any targeted postnatal intervention, however, breastfeeding is also responsible for 8.9 HIV infections per 100 child-years of breastfeeding and accounts for 40% of paediatric HIV infections [3,26].

Furthermore, the longer the duration of breastfeeding, the higher the resulting risk of the postnatal transmission of HIV [24,27,28]. Breastfeeding beyond 6 months is a strong determinant of HIV transmission [28]. The assessment and implementation of interventions to prevent postnatal HIV transmission that will balance this risk of MTCT with the possible adverse outcomes for mother and child health is therefore a challenge.

The first alternative to prolonged breastfeeding is the complete avoidance of breastfeeding, substituted by infant formula. This strategy is currently enforced in Europe and the United States, but the situation is more complex in low-income countries. A second alternative is to shorten the duration of breastfeeding, with an early cessation implemented at approximately 6 months of age. A third potential intervention consists of the promotion of exclusive breastfeeding, e.g. without introducing any other fluids or solids than breastmilk during the first months of life [29–31]. The combination of these last two interventions reduces the cumulative risk of HIV postnatal transmission while retaining the benefits of exclusive breastfeeding during the first months of life.

Given the necessary support, the acceptability of formula feeding and early breastfeeding cessation was high in Abidjan, Côte d'Ivoire [32,33]. In this research setting, no excess in mortality at 18 months was observed in children exposed to alternatives to prolonged breastfeeding when taking into account HIV status [34]. Similarly, in Botswana, the time-to-mortality distributions through 18 months of age were not significantly different between infants receiving 6 months of breastfeeding plus prophylactic infant zidovudine or formula feeding plus one month of zidovudine [35]. Replacement feeding was, however, associated with higher mortality, morbidity, and stigma in less supported field settings [36,37]. Preliminary results from studies conducted in Zambia, Malawi and Kenya suggest increased rates of diarrhoea among children breastfed for 6 months [38–40]. HIV-infected pregnant women must be counselled in choosing a feeding practice adapted to their individual situation, and must be supported in their feeding choice after delivery [41,42].

Other postnatal interventions for the prevention of MTCT include the inactivation of the virus in breastmilk via heat treatment, but their use in a domestic situation requires further practical developments [43,44]. Finally, studies have recently explored the benefits of antiretroviral regimens designed to provide maternal treatment, reducing the maternal plasma HIV viral load, or postexposure prophylaxis to infants during breastfeeding, thus reducing the risk of MTCT in settings in which breastfeeding is common [35,45]. Research is currently underway to assess the usefulness of these strategies [46].

Overall, research has demonstrated that the combination of peripartum and postnatal interventions considerably

reduces MTCT rates with a long-term benefit sustained until the age of 18 months [47]. HIV counselling and testing, antiretroviral prophylactic regimens and infant feeding interventions constitute the basic package of prevention of MTCT services. The proportion of pregnant women being offered prevention of MTCT services has slightly increased from 7.6% in 2003 to 9% in 2005 in low-income countries [48], but global prevention of MTCT coverage remains unacceptably low worldwide. In 30 African countries with the highest HIV prevalence, only 5% of HIV-infected women currently access prevention of MTCT interventions [48]. Operational research initiatives have explored some of the barriers to the prevention of MTCT [49–51]. The implementation of prevention of MTCT services is strongly hindered by the quality of operating health systems [52,53], especially in rural areas: lack of decentralized services, poor monitoring, frequent stock ruptures of test kits and antiretroviral drugs. The promotion of an 'opt-out' approach to prenatal HIV testing [54,55] and, more generally, the adoption of the recently recommended WHO strategy for provider-initiated HIV testing [56] are likely to improve prevention of MTCT coverage. The lack of involvement of male partners is also underlined; pregnant women who are unable to share their HIV status with their partner may be reluctant to accept interventions that would identify them as being HIV infected [57,58]. Finally, innovative family approaches linking the access to HIV care with HIV prevention efforts are a critical step towards improving the transition from prevention of MTCT research to wide-scale practice, but need to be rolled out [19].

Paediatric HIV/AIDS care

In low-income countries, it is estimated that 50% of HIV-infected infants will die before the age of 2 years [59]. Early paediatric HIV diagnosis is thus critical to allow the timely start of appropriate treatment, reduce morbidity and mortality, guide decisions related to child nutrition and improve the quality of life of HIV-infected children [60]. In many low-income countries, however, access to early paediatric HIV diagnosis depends on the local laboratory capacity and the availability of tests, and is often considered too costly and complex. To date, real time polymerase chain reaction is the most valuable and least expensive (less than €20) technology to detect HIV RNA among infants under 18 months of age [61]. Although this technology requires good laboratory infrastructure and human skills, its routine use for programmatic purposes should be encouraged [4]. In rural areas, a dried blood spot (DBS) is used for the collection and storage of blood samples [62,63], although DBS samples still need to be referred to a central laboratory for HIV testing [64]. It is expected that DBS will become the standard tool for improving the coverage of early paediatric HIV diagnosis in low-income countries.

After the confirmed diagnosis of HIV infection, the baseline clinical and laboratory assessment for children should include the clinical staging of HIV disease and the measurement of CD4 cells and T lymphocytes [63].

The prevention of opportunistic infections such as tuberculosis or *Pneumocystis* pneumonia [65] has been the standard of paediatric HIV care for many years. In South Africa, isoniazid prophylaxis reduced the incidence of tuberculosis in HIV-infected children and improved their survival [66]. A Zambian trial demonstrated the efficacy of cotrimoxazole prophylaxis in children older than 12 months [67]. All HIV-exposed children should thus receive cotrimoxazole prophylaxis from the age of 6 weeks in resource-limited settings, irrespective of locally identified resistance to this drug, as recently recommended by WHO [68]. Although cotrimoxazole costs as little as US$0.03 a day, UNAIDS estimates that 4 million children who need this drug do not access it [48].

ART helps HIV-infected children to preserve, enhance, and reconstitute their immune system and therefore reduce the risk of opportunistic infections, to suppress HIV replication, to restore their growth, to improve mental functioning, and overall their quality of life [69–72]. The decision-making process for the initiation of ART in children in low-income countries relies on clinical and immunological assessment [63]. Despite nearly 15 years of experience in the treatment of HIV-infected children in Europe and the United States [73], considerable uncertainty remains as to when to start ART. The benefits of early ART initiation [74,75] need to be balanced against the costs and drawbacks of ART (quality of life, lifelong therapy, viral resistance, adverse effects, and limited second and third-line regimens). WHO recommends that all children classified as WHO paediatric clinical stage 3 or 4 can start ART regardless of the CD4 cell count, total lymphocyte count or the availability of virological test results. Recent data from South Africa from the CHER randomized trial showed that starting antiretroviral drugs within the first 12 weeks of life, rather than starting at the current WHO recommended CD4 cell threshold of 20%, lowered the risk of death [76].

Only a handful of antiretroviral drugs in the current WHO guidelines, however, have solid formulations in doses appropriate for paediatric use and paediatric fixed-dose drug combinations are scarce. Although three recent studies showed satisfactory virological and immunological benefits in children receiving an adult fixed-dose combination ART in fractions [77–79], the lack of pharmacokinetic and pharmacodynamic data on the antiretroviral drugs available to children still contributes to HIV-infected children being underdosed in antiretroviral drugs [80]. There is an urgent need for additional drug formulations for children [81]. In 2007, the first-line antiretroviral regimen recommended by WHO for children includes nevirapine. The immunological and

virological response in infants exposed to nevirapine remains of much concern [82], however, and should be further documented.

Additional research is also critically needed regarding the support to families and health workers who disclose HIV infection to the child [83], and the psychological development of children. A recent South African study reported a 26% disclosure rate among children aged under 6 years [84], although the importance of paediatric disclosure was unanimously acknowledged. The absence of HIV disclosure to a child is associated with non-adherence to treatment [85–87].

Safe and adequate paediatric HIV/AIDS care deserves further research. The implementation and management of a comprehensive package of services for the care of HIV-infected children requires a minimum quality of health services, in terms of human resources and technical equipment, and is thus a major challenge for all-level health facilities in low-income countries.

The provision of paediatric HIV/AIDS care at district level

The expected wide-scale introduction of ART for children is indeed only one aspect of a successful care, support and treatment approach. A comprehensive continuum of care for children should also include HIV counselling and testing, cotrimoxazole prophylaxis for both HIV-exposed and HIV-infected children, regular follow-up of HIV-infected children, and community-based support and counselling of caregivers.

In many low-income countries, however, such comprehensive paediatric HIV/AIDS care faces numerous challenges within the local district health system [88]. The lack of health staff and inadequate healthcare infrastructure is one of the first constraints to the scaling-up of HIV/AIDS care services. Health professionals required to care for HIV-infected children are in short supply in Africa [89]. The identification and referral of children in need of HIV/AIDS care (coming from inpatient wards, adult antiretroviral programmes, rural clinics, community-based organizations, or prevention of MTCT programmes) is also poor. In South Africa, only 10% of children requiring HIV testing at 12 months were actually tested [90]. The improvement in local patient monitoring [91], the decentralization and extension of prevention of MTCT and HIV/AIDS care and support infrastructure into poorly serviced areas, combined with the deployment of mid-level professional cadres and community-level health workers [92,93] are examples of possible solutions. Anonymous HIV screening of all infants at immunization clinics is also feasible to identify HIV-infected children early for referral into care and treatment programmes [94].

Evidence-based guidelines on paediatric HIV/AIDS care, adapted to the capacity of each health facility, are essential. The specific assessment and management of symptomatic HIV infection at the primary healthcare level was recently integrated within the WHO Integrated Management of Childhood Illness guidelines, and evaluated in South Africa [95]. Additional prospective assessments of clinical algorithms is still required to improve paediatric care and treatment [96]. Experience in adult care [97–99] and recently in African children [100,101] advocates for free access at the point of service delivery to paediatric HIV care and treatment including ART.

The various operational constraints to paediatric HIV/AIDS partly explain why currently children represent only 6% of the overall population receiving ART, when this age group represents 14% ($n = 600\,000$) of the total population in need of ART [48]. Political leadership in the fight against HIV/AIDS is, however, steadily growing and several ART programmes are now accessible to children in resource-poor settings [69,71,72,79,102–109].

The research and programmatic experience of caring for children living with HIV-infected family members is also very scarce and highlights the many gaps remaining in the economic, political and social response to children affected by HIV/AIDS.

Children affected by HIV/AIDS

In low-income countries, the vulnerability of children affected by HIV/AIDS is first physical, and is mainly related to the impact of HIV/AIDS on household economies. The illness or death of a breadwinner leads to difficulties in responding to the basic needs of family members, including accessing antiretroviral drugs. Uninfected children born to HIV-positive mothers thus experience their mother's illness and death at a young age, which contributes to putting them at risk of increased morbidity and mortality [59,110,111]. To date, however, there is only limited evidence of ill health among young orphans who have survived their mother's death [112,113].

The psychological impact of HIV/AIDS on children in low-income countries has been greatly underestimated, and yet the world of a child living in a family affected by HIV/AIDS goes through many changes. These children have to witness the physical deterioration and pain of their HIV-infected parents, especially when they are unaware of the nature of the illness affecting their parent(s) or refuse to acknowledge HIV infection. Children are anxious about their source of livelihood and their ability to retain the family home after the parent's death; separation from siblings is a frequent and important source of trauma [114,115]. The serial loss of adult figures and carers such as parents, teachers or mentors is also likely to

create a sense of insecurity or abandonment. Overall, much remains to be understood on the psychological consequences of HIV/AIDS among children, including the specific emotional effects by age, type of orphan and living arrangements.

Research and intervention studies on counselling, emotional and social support for children affected by HIV/AIDS are scarce and are mostly focused on the specific difficulties and traumas of orphans. In rural Uganda, access to mental health services was shown to benefit all orphans, regardless of family situations [116]. The number of health workers specializing in mental health, however, remains insufficient in most low-income countries [117]. In Zimbabwe, peer education programmes involving the community and developing ties between orphans and non-orphans have built up the self esteem of children affected by HIV/AIDS and discouraged stigmatization [118]. Schools also play a significant role in the socio-emotional development of children, especially of orphans and children affected by AIDS. Unfortunately, in countries severely affected by the HIV/AIDS epidemic, the supply and quality of education services are severely constrained [119]. In Zimbabwe, orphans were less likely to be enrolled in school than non-orphans of the same age, as a result of poverty, the priority given to core family children and stigmatization [120].

The legislative and governmental support to children affected by HIV/AIDS is influenced by the stability of the political environment, which is rare in many of the countries severely hit by the HIV/AIDS epidemic [121]. In 2003, of the 40 sub-Saharan countries with generalized epidemics (adult HIV prevalence reaching 1% or above), only six (15%) had developed a national policy on orphans and HIV/AIDS. [122].

This breakdown in governmental support systems may explain why families and communities have been described as the key caregivers of children affected by HIV/AIDS. In traditional African cultures, the practices of child fostering, by which children are cared for by non-biological parents, predate the HIV epidemic [123,124]. In the era of HIV, these traditional practices have been preserved [125,126]. There is concern over whether child fostering within the extended family will be able meet the expected increase in the number of orphans [127,128]. This concern has encouraged the development of community-based initiatives from 'external actors' (other than families) to endorse orphan care: residential community centres [129]; small, family-based orphanages; or orphanages supported by donors sponsoring non-governmental organizations [130]. Many of these orphan care strategies have been shown to be inadequate for large-scale implementation and are unsustainable because they are based on donor funding. Overall, research has shown that caregivers of children affected by HIV/AIDS and service providers tend to work

in isolation from each other, with little networking between approaches [121].

A number of model frameworks have been developed by Family Health International [131] or USAID [132] for responding to the needs of children affected by HIV/AIDS and orphans. By the end of 2005, nearly 30 diverse organizations had endorsed the USAID framework, signalling wide acceptance to shape effective responses to the growing problem of children affected by HIV/AIDS [48].

In conclusion, during the past two decades, international efforts to fight against HIV/AIDS have yielded important research successes for child survival in low-income countries. The transition from research to action, however, remains largely insufficient. Improving the coverage of prevention of MTCT should be a priority. There is also currently enough evidence to roll out paediatric HIV care and treatment, at least at the same speed and extent as adult care. This requires improving healthcare systems as well as political commitment and funding at international and national levels. Current knowledge indicates that orphans and vulnerable children pay a large tribute to HIV/AIDS and deserve a large-scale response. Finally, the fight against HIV/AIDS requires the scaling-up and intensification of primary HIV prevention, as part of a comprehensive response that simultaneously expands access to treatment and care.

Acknowledgements

References

1. UNAIDS. *AIDS epidemic update – special report on HIV/AIDS*. December 2006, Geneva, Switzerland: UNAIDS; 2006.
2. UNICEF. *Africa's orphaned and vulnerable generations. Children affected by AIDS*. New York, USA: UNICEF; 2006.
3. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, *et al*. **Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice.** *JAMA* 2000; **283**:1175–1182.

4. World Health Organization. *Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings. Towards universal access. Recommendations for a public health approach.* Geneva, Switzerland: WHO; 2006:92.

5. Stanton CK, Holtz SA. **Levels and trends in cesarean birth in the developing world.** *Studies Family Plann* 2006; **37**:41–48.

6. Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. **Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial.** *Lancet* 1999; **353**:781–785.

7. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. **Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.** *Lancet* 1999; **354**:795–802.

8. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. **Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group.** *Lancet* 1999; **353**:773–780.

9. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. **6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant.** *Lancet* 1999; **353**:786–792.

10. Dabis F, Bequet L, Ekouevi DK, Viho I, Rouet F, Horo A, et al. **Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.** *AIDS* 2005; **19**:309–318.

11. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. **Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.** *N Engl J Med* 2004; **351**:217–228.

12. Petra Study Team. **Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra Study): a randomised, double-blind, placebo-controlled trial.** *Lancet* 2002; **359**:1178–1186.

13. Leroy V, Sakarovitch C, Cortina-Borja M, McIntyre J, Coovadia H, Dabis F, et al. **Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?** *AIDS* 2005; **19**:1865–1875.

14. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. **Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.** *Lancet* 2003; **362**:859–868.

15. Eshleman SH, Jackson JB. **Nevirapine resistance after single dose prophylaxis.** *AIDS Rev* 2002; **4**:59–63.

16. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, et al. **Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.** *Int J Epidemiol* 2007; E-pub ahead of print. doi:10.1093/ije/dym104.

17. McIntyre J. **Preventing mother-to-child transmission of HIV: successes and challenges.** *Br J Obstet Gynaecol* 2005; **112**:1196–1203.

18. Chaix ML, Ekouevi DK, Rouet F, Tonwe-Gold B, Viho I, Bequet L, et al. **Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA DITRAME Plus, Abidjan, Cote d'Ivoire.** *J Infect Dis* 2006; **193**:482–487.

19. Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, et al. **Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.** *PLoS Med* 2007; **4**:e257.

20. Palombi L, Germano P, Liotta G, Guidotti G, Narcisco P, Perno CF, et al. **DREAM Program: 6-month follow-up of the prevention of mother-to-child transmission service.** In: *13th Conference on Retroviruses and Opportunistic Infections.* Denver, CO, USA, 5–8 February 2006.

21. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. **Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?** *J Infect Dis* 2006; **193**:1195–1201.

22. Thorne C, Patel D, Newell ML. **Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe.** *AIDS* 2004; **18**:2337–2339.

23. Briand N, Lallemant M, Jourdain G, Techapalokul S, Tunthanathip P, Suphanich S, et al. **Haematological safety of perinatal zidovudine in pregnant HIV-1-infected women in Thailand: secondary analysis of a randomized trial.** *PLoS Clin Trials* 2007; **2**:e11.

24. Leroy V, Karon JM, Alioum A, Ekpini ER, Meda N, Greenberg AE, et al. **Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa.** *AIDS* 2002; **16**:631–641.

25. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. **Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis.** *Lancet* 2000; **355**:451–455.

26. Breastfeeding and HIV International Transmission Study Group. **Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis.** *J Infect Dis* 2004; **189**:2154–2166.

27. Leroy V, Karon JM, Alioum A, Ekpini ER, Van de Perre P, Greenberg AE, et al. **Postnatal transmission of HIV-1 after a maternal short-course zidovudine peripartum regimen in West Africa.** *AIDS* 2003; **17**:1493–1501.

28. Taha TE, Hoover DR, Kumwenda NI, Fiscus SA, Kafulafula G, Nkhoma C, et al. **Late postnatal transmission of HIV-1 and associated factors.** *J Infect Dis* 2007; **196**:10–14.

29. Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai WY, Coovadia HM. **Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa.** *AIDS* 2001; **15**:379–387.

30. Iliff PJ, Piwoz EG, Tavengwa NV, Zunguza CD, Marinda ET, Nathoo KJ, et al. **Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival.** *AIDS* 2005; **19**:699–708.

31. Coovadia HM, Rollins NC, Bland RM, Little K, Coutsoudis A, Bennish ML, Newell ML. **Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study.** *Lancet* 2007; **369**:1107–1116.

32. Becquet R, Ekouevi DK, Viho I, Sakarovitch C, Toure H, Castetbon K, et al. **Acceptability of exclusive breastfeeding with early cessation to prevent HIV transmission through breastmilk, ANRS 1201/1202 DITRAME Plus, Abidjan, Côte d'Ivoire.** *J Acquir Immune Defic Syndr* 2005; **40**:600–608.

33. Leroy V, Sakarovitch C, Viho I, Becquet R, Ekouevi DK, Bequet L, et al. **Acceptability of formula-feeding to prevent HIV postnatal transmission, Abidjan, Cote d'Ivoire – ANRS 1201/1202 DITRAME Plus study.** *J Acquir Immune Defic Syndr* 2007; **44**:77–86.

34. Becquet R, Ekouevi DK, Sakarovitch C, Viho I, Bequet L, Fassinou P, et al. **Two-year morbidity and mortality and alternatives to prolonged breastfeeding among children born to HIV-infected mothers: ANRS 1201/1202 DITRAME Plus, Abidjan, Côte d'Ivoire.** *PLoS Med* 2007; **4**:e17.

35. Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Heymann SJ, et al. **Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana – a randomized trial: the Mashi Study.** *JAMA* 2006; **296**:794–805.

36. Bahl R, Frost C, Kirkwood BR, Edmond K, Martines J, Bhandari N, Arthur P. **Infant feeding patterns and risks of death and hospitalization in the first half of infancy: multicentre cohort study.** *Bull WHO* 2005; **83**:418–426.

37. Doherty T, Chopra M, Nkonki L, Jackson D, Greiner T. **Effect of the HIV epidemic on infant feeding in South Africa: "When they see me coming with the tins they laugh at me".** *Bull WHO* 2006; **84**:90–96.

38. Kourtis AP, Fitzgerald D, Hyde L, Tien HC, Chavula C, Mumba N, *et al.* **Diarrhea in uninfected infants of HIV-infected mothers who stop breastfeeding at 6 months: the BAN study experience**. In: *14th Conference on Retroviruses and Opportunistic Infections*. Los Angeles, CA, USA, 25–28 February 2007.

39. Thomas T, Masaba R, Van Eijk A, Ndivo R, Nasokho P, Thigpen M, Fowler MG. **Rates of diarrhea associated with early weaning among infants in Kisumu, Kenya**. In: *14th Conference on Retroviruses and Opportunistic Infections*. Los Angeles, CA, USA, 25–28 February 2007.

40. Sinkala M, Kuhn L, Kankasa C, Kasonde P, Vwalika C, Mwiya M, *et al.* **No benefit of early cessation of breastfeeding at 4 months on HIV-free survival of infants born to HIV-infected mothers in Zambia: the Zambia Exclusive Breastfeeding Study**. In: *14th Conference on Retroviruses and Opportunistic Infections*. Los Angeles, CA, USA, 25–28 February 2007.

41. Bland RM, Rollins NC, Coovadia HM, Coutsoudis A, Newell ML. **Infant feeding counselling for HIV-infected and uninfected women: appropriateness of choice and practice**. *Bull WHO* 2007; **85**:289–296.

42. World Health Organization. *WHO HIV and Infant Feeding Technical Consultation held on behalf of the Inter-agency Task Team (IATT) on prevention of hiv infections in pregnant women, mothers and their infants*. Geneva, Switzerland: WHO; 25–27 October 2006.

43. Jeffery BS, Mercer KG. **Pretoria pasteurisation: a potential method for the reduction of postnatal mother to child transmission of the human immunodeficiency virus**. *J Trop Pediatr* 2000; **46**:219–223.

44. Israel-Ballard K, Chantry C, Dewey K, Lonnerdal B, Sheppard H, Donovan R, *et al.* **Viral, nutritional, and bacterial safety of flash-heated and Pretoria-pasteurized breast milk to prevent mother-to-child transmission of HIV in resource-poor countries: a pilot study**. *J Acquir Immune Defic Syndr* 2005; **40**:175–181.

45. Gaillard P, Fowler MG, Dabis F, Coovadia H, vanderHorst C, vanRompay K, *et al.* **Use of antiretroviral drugs to prevent HIV-1 transmission through breast-feeding: from animal studies to randomized clinical trials**. *J Acquir Immune Defic Syndr* 2004; **35**:178–187.

46. Becquet R. **Antiretroviral therapy among HIV-infected breast-feeding mothers: a promising strategy to prevent HIV transmission through breastmilk in Africa**. *Future HIV Ther* 2007; **1**:17–21.

47. Leroy V, Ekouevi DK, Dequae-Merchadou L, Viho I, Becquet R, Tonwe-Gold B, *et al.* **18-Month effectiveness of short-course perinatal antiretroviral regimens combined to infant-feeding interventions for PMTCT in Abidjan, Côte d'Ivoire. DITRAME PLUS ANRS 1201/1202 2001–2005**. In: *XVIth International AIDS Conference*. Toronto, Canada, 13–18 August 2006.

48. UNAIDS. *2006 Report on the global AIDS epidemic*. Geneva, Switzerland: UNAIDS: 2006.

49. Thaineua V, Kanshana S, Thewanda D, Amornwichet P, Kullerk N, Voramongkol N, *et al.* **Evaluation of a regional pilot program to prevent mother-infant HIV transmission – Thailand, 1998–2000 (Reprinted from *MMWR* 2001; 50:599)**. *JAMA* 2001; **286**:784–786.

50. Perez-Then E, Pena R, Tavarez-Rojas M, Pena C, Quinonez S, Buttler M, *et al.* **Preventing mother-to-child HIV transmission in a developing country: the Dominican Republic experience**. *J Acquir Immune Defic Syndr* 2003; **34**:506–511.

51. Stringer EM, Sinkala M, Stringer JS, Mzyece E, Makuka I, Goldenberg RL, *et al.* **Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia**. *AIDS* 2003; **17**:1377–1382.

52. Behets F, Matendo R, Vaz LME, Kilese N, Nanlele D, Kokolomami J, *et al.* **Preventing vertical transmission of HIV in Kinshasa, Democratic Republic of the Congo: a baseline survey of 18 antenatal clinics**. *Bull WHO* 2006; **84**:969–975.

53. Jackson DJ, Chopra M, Doherty TM, Colvin MSE, Levin JB, Willumsen JF, *et al.* **Operational effectiveness and 36 week HIV-free survival in the South African programme to prevent mother-to-child transmission of HIV-1**. *AIDS* 2007; **21**:509–516.

54. Perez F, Zvandaziva C, Engelsmann B, Dabis F. **Acceptability of routine HIV testing ("opt-out") in antenatal services in two rural districts of Zimbabwe**. *J Acquir Immune Defic Syndr* 2006; **41**:514–520.

55. Chandisarewa W, Stranix-Chibanda L, Chirapa E, Miller A, Simoyi M, Mahomva A, *et al.* Routine offer of antenatal HIV testing ("opt-out" approach) to prevent mother-to-child transmission of HIV in urban Zimbabwe. Bull WHO, 2007; In press.

56. World Health Organization, UNAIDS. *Guidance on provider-initiated HIV testing and counselling in health facilities, May 2007*. Geneva, Switzerland: WHO; 2007:56.

57. Painter TM. **Voluntary counseling and testing for couples: a high-leverage intervention for HIV/AIDS prevention in sub-Saharan Africa**. *Soc Sci Med* 2001; **53**:1397–1411.

58. Homsy J, Kalamya JN, Obonyo J, Ojwang J, Mugumya R, Opio C, Mermin J. **Routine intrapartum HIV counseling and testing for prevention of mother-to-child transmission of HIV in a rural Ugandan hospital**. *J Acquir Immune Defic Syndr* 2006; **42**:149–154.

59. Newell ML, Coovadia H, Cortina Borja M, Rollins N, Gaillard P, Dabis F. **Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis**. *Lancet* 2004; **364**:1236–1243.

60. Prendergast A, Tudor-Williams G, Jeena P, Burchett S, Goulder P. **International perspectives, progress, and future challenges of paediatric HIV infection**. *Lancet* 2007; **370**:68–80.

61. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, *et al.* **Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting**. *J Clin Microbiol* 2005; **43**:2709–2717.

62. Ou CY, Yang H, Balinandi S, Sawadogo S, Shanmugam V, Tih PM, *et al.* **Identification of HIV-1 infected infants and young children using real-time RT PCR and dried blood spots from Uganda and Cameroon**. *J Virol Methods* 2007; **144**:109–114.

63. World Health Organization. *Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach*. Geneva, Switzerland: WHO; 2006.

64. Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS. **Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings**. *J Acquir Immune Defic Syndr* 2005; **38**:615–617.

65. Lucas SB, Peacock CS, Hounnou A, Brattegaard K, Koffi K, Honde M, *et al.* **Disease in children infected with HIV in Abidjan, Cote d'Ivoire**. *BMJ* 1996; **312**:335–338.

66. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, *et al.* **Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial**. *BMJ* 2007; **334**:136.

67. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, *et al.* **Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial**. *Lancet* 2004; **364**:1865–1871.

68. World Health Organization. *Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults in resource-limited settings. Recommendations for a public health approach*. Geneva, Switzerland: WHO; 2006:64.

69. Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, Timite M, *et al.* **Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire**. *AIDS* 2004; **18**:1905–1913.

70. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, *et al.* **Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1**. *N Engl J Med* 2001; **345**:1522–1528.

71. Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, Sirisanthana V. **Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program**. *Clin Infect Dis* 2005; **41**:100–107.

72. Rouet F, Fassinou P, Inwoley A, Anaky MF, Kouakoussui A, Rouzioux C, *et al.* **Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens**. *AIDS* 2006; **20**:2315–2319.

73. Thorne C, Gray L, Newell ML. **Management of vertically HIV-infected children in Europe.** *Acta Paediatr* 2003; **92**:246–250.

74. Newell ML, Patel D, Goetghebuer T, Thorne C. **CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation?** *J Infect Dis* 2006; **193**:954–962.

75. Faye A, Le Chenadec J, Dollfus C, Thuret I, Douard D, Firtion G, *et al.* **Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1.** *Clin Infect Dis* 2004; **39**:1692–1698.

76. Violari A, Cotton M, Gibb D, Babiker A, Steyn J, Jean-Philippe P, McIntyre J. **ART initiated before 12 weeks reduces early mortality in young children HIV-infected infants: evidence from the children with HIV Early Antiretroviral Therapy (CHER) Study**. In: *4th IAS Conference on HIV Pathogenesis, Treatment and Prevention*. Sydney, Australia, 22–25 July 2007.

77. Barlow-Mosha L, Musoke P, Ajuna P, Luttajumwa M, Walabyeki J, Owor M, Mubiru M. **Early effectiveness of Triomune in HIV infected Ugandan children**. In: *3rd IAS Conference on HIV Pathogenesis and Treatment*. Rio de Janeiro, Brazi, 24–27 July 2005.

78. Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, *et al.* **Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.** *AIDS* 2005; **19**:1495–1499.

79. O'Brien DP, Sauvageot D, Zachariah R, Humblet P. **In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy.** *AIDS* 2006; **20**:1955–1960.

80. Menson EN, Walker AS, Sharland M, Wells C, Tudor-Williams G, Riordan FA, *et al.* **Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997–2005: cohort study.** *BMJ* 2006; **332**:1183–1187.

81. Calmy A, Klement E, Teck R, Berman D, Pecoul B, Ferradini L. **Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up.** *AIDS* 2004; **18**:2353–2360.

82. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, *et al.* **Response to antiretroviral therapy after a single, peripartum dose of nevirapine.** *N Engl J Med* 2007; **356**:135–147.

83. Myer L, Moodley K, Hendricks F, Cotton M. **Healthcare providers' perspectives on discussing HIV status with infected children.** *J Trop Pediatr* 2006; **52**:293–295.

84. Moodley K, Myer L, Michaels D, Cotton M. **Paediatric HIV disclosure in South Africa – caregivers' perspectives on discussing HIV with infected children.** *S Afr Med J* 2006; **96**:201–204.

85. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. **The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children.** *Pediatr Infect Dis J* 2004; **23**:1035–1041.

86. Wiener L, Mellins CA, Marhefka S, Battles HB. **Disclosure of an HIV diagnosis to children: history, current research, and future directions.** *J Dev Behav Pediatr* 2007; **28**:155–166.

87. Bikaako-Kajura W, Luyirika E, Purcell DW, Downing J, Kaharuza F, Mermin J, *et al.* **Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda.** *AIDS Behav* 2006; **10**:S85–S93.

88. De Baets AJ, Bulterys M, Abrams EJ, Kankassa C, Pazvakavambwa IE. **Care and treatment of HIV-infected children in Africa: issues and challenges at the district hospital level.** *Pediatr Infect Dis J* 2007; **26**:163–173.

89. Kline MW. **Perspectives on the pediatric HIV/AIDS pandemic: catalyzing access of children to care and treatment.** *Pediatrics* 2006; **117**:1388–1393.

90. Doherty T, Beeser M, Donohue S, Kamoga N, Stoops N, Williamson L, Visser R. *An evaluation of the prevention of mother-to-child transmission (PMTCT) of HIV initiative in South Africa, lessons and key recommendations*. Durban, South Africa: Health Systems Trust; 2003.

91. Stranix-Chibanda L, Chandisarerwa W, Chirapa E, Shetty A. **Low return rates for routine follow-up of HIV-exposed infants at primary care level in an urban area of Zimbabwe**. In: *PEPFAR Implementers Meeting*. Durban, South Africa, 12–15 June 2006.

92. Kober K, Van Damme W. **Scaling up access to antiretroviral treatment in southern Africa: who will do the job?** *Lancet* 2004; **364**:103–107.

93. Schneider H, Blaauw D, Gilson L, Chabikuli N, Goudge J. **Health systems and access to antiretroviral drugs for HIV in Southern Africa: service delivery and human resources challenges.** *Reprod Health Matters* 2006; **14**:12–23.

94. Rollins N, Little K, Mzolo S, Horwood C, Newell ML. **Surveillance of mother-to-child transmission prevention programmes at immunization clinics: the case for universal screening.** *AIDS* 2007; **21**:1341–1347.

95. Horwood C, Liebeschuetz S, Blaauw D, Cassol S, Qazi S. **Diagnosis of paediatric HIV infection in a primary healthcare setting with a clinical algorithm.** *Bull WHO* 2003; **81**:858–866.

96. Jones SA, Sherman GG, Coovadia AH. **Can clinical algorithms deliver an accurate diagnosis of HIV infection in infancy?** *Bull WHO* 2005; **83**:559–560.

97. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, *et al.* **Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.** *Lancet* 2006; **367**:817–824.

98. Dabis F, Balestre E, Braitstein P, Miotti P, Brinkhof WG, Schneider M, *et al.* **Cohort profile: Antiretroviral Therapy in Lower Income Countries (ART–LINC): international collaboration of treatment cohorts.** *Int J Epidemiol* 2005; **34**:979–986.

99. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, *et al.* **Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.** *Lancet* 2006; **367**:1335–1342.

100. Arrivé E, Marquis B, Tumweisiye N, Cotton M, Holland M, Renner L, *et al.* **Response to ART in children in sub-saharan africa: a pooled analysis of clinical databases, the KIDS–ART–LINC collaboration**. In: *14th Conference on Retroviruses and Opportunistic Infections*. Los Angeles, CA, USA, 25–28 February 2007.

101. MboriNgacha D, Kyabayinze D, Arrivé E, Marquis B, Tumwesigye N, Kieffer MP, *et al.* **Paediatric ART in sub-Saharan Africa: program characteristics in the multicenter international KIDS–ART–LINC collaboration**. In: *XVIth International AIDS Conference*. Toronto, Canada, 13–18 August 2006.

102. George E, Noel F, Bois G, Cassagnol R, Estavien L, Rouzier Pde M, *et al.* **Antiretroviral therapy for HIV-1-infected children in Haiti.** *J Infect Dis* 2007; **195**:1411–1418.

103. World Health Organization. *Progress on Global Access to HIV Antiretroviral Therapy. An update on ''3 by 5''*. Geneva, Switzerland: WHO; June 2005.

104. Office of the United States Global AIDS Coordinator. *Engendering bold leadership: the President's Emergency Plan For AIDS Relief, first annual report to Congress*. Washington, USA: Office of the United States Global AIDS Coordinator; 2006.

105. Mailman School of Public Health – Columbia University. MTCT-Plus Initiative Activity Report. Annual report year 3. 1 January–31 December 2004. New York, USA: Mailman School of Public Health, Columbia University; 2004.

106. Elizabeth Glaser Pediatric AIDS Foundation. *International family AIDS initiatives*. Washington, DC, USA, 2006.

107. Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, *et al.* **Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.** *BMC Pediatr* 2007; **7**:7–13.

108. Arrive E, Kyabayinze DJ, Marquis B, Tumwesigye N, Kieffer MP, Azondekon A, *et al.* **Cohort profile: the Paediatric Antiretroviral Treatment Programmes in Lower-Income Countries (KIDS–ART–LINC) Collaboration**. *Int J Epidemiol* 2007; In press.

109. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, *et al.* **Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary healthcare facilities in Zambia.** *JAMA* 2007; **298**:1888–1899.

110. Ngweshemi J, Urassa T, Isingo T, Mwaluko G, Ngalula J, Boerma T, *et al.* **HIV impact on mother and child mortality in rural Tanzania.** *J Acquir Immune Defic Syndr* 2003; **33**:393–404.

111. Nakiyingi JS, Bracher M, Whitworth JA, Ruberantwari A, Busingye J, Mbulaiteye SM, Zaba B. **Child survival in relation to mother's HIV infection and survival: evidence from a Ugandan cohort study.** *AIDS* 2003; **17**:1827–1834.

112. Watts H, Gregson S, Saito S, Lopman B, Beasley M, Monasch R. **Poorer health and nutritional outcomes in orphans and vulnerable young children not explained by greater exposure to extreme poverty in Zimbabwe.** *Trop Med Int Health* 2007; **12**:584–593.

113. Miller CM, Gruskin S, Subramanian SV, Heymann J. **Emerging health disparities in Botswana: examining the situation of orphans during the AIDS epidemic.** *Soc Sci Med* 2007; **64**:2476–2486.

114. USAID/Zambia. *Results of the orphans and vulnerable children head of household baseline survey in four districts in Zambia. Displaced Children and Orphans Fund, SCOPE-OVC/Zambia.* Arlington, USA: Family Health International; 2002.

115. Sengendo J, Nambi J. **The psychological effect of orphanhood: a study of orphans in Rakai district.** *Health Transit Rev* 1997; **7 (Suppl)**:105–124.

116. Atwine B, Cantor-Graae E, Bajunirwe F. **Psychological distress among AIDS orphans in rural Uganda.** *Soc Sci Med* 2005; **61**:555–564.

117. Pillay AL, Lockhat MR. **Developing community mental health services for children in South Africa.** *Soc Sci Med* 1997; **45**:1493–1501.

118. UNAIDS. *Investing in our future. psychosocial support for children affected by HIV/AIDS. A case study in Zimbabwe and the United Republic of Tanzania.* Geneva, Switzerland: UNAIDS; 2001:75.

119. Case A, Paxson C, Ableidinger J. **Orphans in Africa: parental death, poverty, and school enrollment.** *Demography* 2004; **41**:483–508.

120. Nyamukapa C, Foster G, Gregson S. **Orphans' household circumstances and access to education in a maturing HIV epidemic in eastern Zimbabwe.** *J Soc Dev Afr* 2003; **18**:7–32.

121. Madhavan S. **Fosterage patterns in the age of AIDS: continuity and change.** *Soc Sci Med* 2004; **58**:1443–1454.

122. UNICEF. *Africa's orphaned generations.* New York, USA: UNICEF; 2003.

123. Ntozi JP. **Effect of AIDS on children: the problem of orphans in Uganda.** *Health Transit Rev* 1997; **7 (Suppl)**:23–40.

124. Foster G, Williamson J. **A review of current literature on the impact of HIV/AIDS on children in sub-Saharan Africa.** *AIDS* 2000; **14**:S275–S284.

125. Audemard C, Kokou V, Desgrees du Loû A. *Orphans and children vulnerable as a result of AIDS in Africa [in French]. Les Numériques du CEPED.* Paris, France: CEPED; 2006.

126. Monasch R, Boerma JT. **Orphanhood and childcare patterns in sub-Saharan Africa: an analysis of national surveys from 40 countries.** *AIDS* 2004; **18 (Suppl 2)**:S55–S65.

127. Foster G. **Supporting community efforts to assist orphans in Africa.** *N Engl J Med* 2002; **346**:1907–1910.

128. Miller CM, Gruskin S, Subramanian SV, Rajaraman D, Heymann SJ. **Orphan care in Botswana's working households: growing responsibilities in the absence of adequate support.** *Am J Public Health* 2006; **96**:1429–1435.

129. Jackson H, Kerkhoven R. **Developing AIDS care in Zimbabwe: a case for residential community centres?** *AIDS Care* 1995; **7**:663–673.

130. Matshalaga NR, Powell G. **Mass orphanhood in the era of HIV/AIDS.** *BMJ* 2002; **324**:185–186.

131. Family Health International. *Care for orphans, children affected by HIV/AIDS and other vulnerable children. A strategic framework.* Arlington, USA: Family Health International; 2001.

132. UNAIDS, UNICEF, USAID. *Children on the Brink 2004. A joint report of new orphan estimates and a framework for action.* Geneva, Switzerland; New York, USA; Washington, USA: UNAIDS, UNICEF, USAID; 2004.